Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Table 1 shows the baseline characteristics.Baseline characteristics of children with SSNS at 4 weeks after first presentationAll ages(N = 40)Country of residence, n (%) Belgium5 (12.5) Netherlands35 (87.5)Age (years), median (min, max)6.34 (2.6, 15.5)Male, n (%)25 (62.5)Parent born in the Netherlands/Belgium33 (82.5)Educational level of parent, n (%)a Low6 (15.0) Intermediate13 (32.5) High21 (52.5)Time to remission (days), median (min, max)10 (5, 30) Late remission (> 10 days after start treatment), n (%)20 (50.0)Prescribed prednisolone dose (mg/dose), mean (SD)51.0 (9.4)Cumulative prednisolone dose (mg), mean (SD)1590 (354)Cumulative prednisolone dose (mg/m2), mean (SD)1890 (667)Illness in past 4 weeks, n (%)11 (27.5) Days of illness, median (min, max)b2 (1, 10) Illness for > 1 week, n (%)b1 (2.5)School absence in past 4 weeks, n (%)14 (35.0) Days of school absence, median (min, max)b10 (1, 28) School absence for > 1 weekb8 (20.0)Presence of steroid side-effects, n (%)34 (85.0) Binge eating, n (%)25 (62.5) Moon face, n (%)22 (55.0) Behavioural changes, n (%)17 (42.5) Mood changes, n (%)18 (45.0) Weight gain, n (%)12 (30.0)Use of concomitant medication, n (%)35 (87.5) Number of used medications, mean (SD)2.25 (1.1) Vitamin D, n (%)34 (85.0) Proton pump inhibitors, n (%)11 (27.5) Antihypertensive medication, n (%)4 (10.0) Inhalation medication, n (%)3 (7.5) Antibiotics, n (%)3 (7.5) Allergy medication, n (%)2 (5.0) Other, n (%)11 (27.5)aLow: primary education, lower vocational education, lower or middle general secondary education; Intermediate: middle vocational education, higher secondary education, pre-university education; High: higher vocational education, universitybProportion of children who were ill or missed school in the past 4 weeks

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Children were followed until 2 years after first onset.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Health-related quality of life of children with first onset steroid-sensitive nephrotic syndrome

Study design awaiting verification · European Journal of Pediatrics · 2023

Original publication title

Health-related quality of life of children with first onset steroid-sensitive nephrotic syndrome

Floor Veltkamp; Lorynn Teela; Michiel A. J. Luijten; Hedy A. van Oers; Elske M. Mak-Nienhuis; Lotte Haverman; Antonia H. M. Bouts; on behalf of the LEARNS consortiumAdeelAbdulBaelAnnaBoutsAntonia H. M.ButerNynke H.van der DeureHansDorresteijnEiskeFlorquinSandrineGracchiValentinaHoruzFloreKloosterman-EijgenraamFrancisLevtchenkoElenaMak-NienhuisElske M.MathôtRon A. A.OversteegeFloorde PontSaskiavan Rooij-KouwenhovenRoos W. G.SchreuderMichiel F.SchriemerRixtVosPaulWalleJohan Vandevan WijkJoanna A. E.

© The Author(s) 2023

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

This study assessed HRQoL and emotional and behavioral difficulties (EBD) and associated variables in children with first onset SSNS. While relapsing steroid-sensitive nephrotic syndrome (SSNS) in children is associated with lower health-related quality of life (HRQoL), little is known about first onset. Four weeks after onset, children (2 to 16 years) and/or their parents who participated in a randomized placebo-controlled trial, completed the Pediatric Quality of Life Inventory 4.0 (PedsQL) and Strengths and Difficulties Questionnaire (SDQ) to measure HRQoL and EBD, respectively.

Total and subscale scores and the proportion of children with impaired HRQoL (> 1 SD below the mean of the reference group) or SDQ clinical scores (< 10th and > 90th percentile) were compared to the Dutch general population (reference group). Regression analyses were used to identify associated variables. Compared to the reference group, children 8 to 18 years reported significantly lower total HRQoL, and physical and emotional functioning. A large proportion (> 45%) of these children had impaired HRQoL.

There were no differences in HRQoL between children 2 to 7 years and the reference group, except for higher scores on social functioning (5 to 7 years). Similar proportions of SSNS and reference children scored within the clinical range of SDQ subscales. Age, sex, and steroid side-effects were negatively associated with HRQol and/or EBD.

   Conclusion: This study showed that HRQoL and EBD are affected in children of different ages with first onset SSNS. This calls for more awareness from healthcare providers and routinely monitoring of HRQoL and EBD in daily clinical care to prevent worsening of symptoms.

   Clinical trial registry: Netherlands Trial Register (https://trialsearch.who.int/; NTR7013), date of registration: 02 June 2018.

What is Known:

•  Health-related quality of life (HRQoL) is lower and emotional and behavioral difficulties (EBD) is more affected in children with frequently-relapsing and steroid-dependent nephrotic syndrome.

What is New:

•  HRQoL and EBD are affected in children with first onset steroid-sensitive nephrotic syndrome compared to a reference group of the Dutch general population.

• To what extent HRQoL and EBD are affected depends on the age of the patient.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00431-023-05135-5.

Authors’ abstract

This study assessed HRQoL and emotional and behavioral difficulties (EBD) and associated variables in children with first onset SSNS. While relapsing steroid-sensitive nephrotic syndrome (SSNS) in children is associated with lower health-related quality of life (HRQoL), little is known about first onset. Four weeks after onset, children (2 to 16 years) and/or their parents who participated in a randomized placebo-controlled trial, completed the Pediatric Quality of Life Inventory 4.0 (PedsQL) and Strengths and Difficulties Questionnaire (SDQ) to measure HRQoL and EBD, respectively.

Total and subscale scores and the proportion of children with impaired HRQoL (> 1 SD below the mean of the reference group) or SDQ clinical scores (< 10th and > 90th percentile) were compared to the Dutch general population (reference group). Regression analyses were used to identify associated variables. Compared to the reference group, children 8 to 18 years reported significantly lower total HRQoL, and physical and emotional functioning. A large proportion (> 45%) of these children had impaired HRQoL.

There were no differences in HRQoL between children 2 to 7 years and the reference group, except for higher scores on social functioning (5 to 7 years). Similar proportions of SSNS and reference children scored within the clinical range of SDQ subscales. Age, sex, and steroid side-effects were negatively associated with HRQol and/or EBD.

   Conclusion: This study showed that HRQoL and EBD are affected in children of different ages with first onset SSNS. This calls for more awareness from healthcare providers and routinely monitoring of HRQoL and EBD in daily clinical care to prevent worsening of symptoms.

   Clinical trial registry: Netherlands Trial Register (https://trialsearch.who.int/; NTR7013), date of registration: 02 June 2018.

What is Known:

•  Health-related quality of life (HRQoL) is lower and emotional and behavioral difficulties (EBD) is more affected in children with frequently-relapsing and steroid-dependent nephrotic syndrome.

What is New:

•  HRQoL and EBD are affected in children with first onset steroid-sensitive nephrotic syndrome compared to a reference group of the Dutch general population.

• To what extent HRQoL and EBD are affected depends on the age of the patient.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00431-023-05135-5.

Publication and source details

Original title: Health-related quality of life of children with first onset steroid-sensitive nephrotic syndrome

Floor Veltkamp; Lorynn Teela; Michiel A. J. Luijten; Hedy A. van Oers; Elske M. Mak-Nienhuis; Lotte Haverman; Antonia H. M. Bouts; on behalf of the LEARNS consortiumAdeelAbdulBaelAnnaBoutsAntonia H. M.ButerNynke H.van der DeureHansDorresteijnEiskeFlorquinSandrineGracchiValentinaHoruzFloreKloosterman-EijgenraamFrancisLevtchenkoElenaMak-NienhuisElske M.MathôtRon A. A.OversteegeFloorde PontSaskiavan Rooij-KouwenhovenRoos W. G.SchreuderMichiel F.SchriemerRixtVosPaulWalleJohan Vandevan WijkJoanna A. E.

European Journal of Pediatrics · 2023

Communicated by Peter de Winter

© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/501100002997NierstichtingCP16.03CP16.03CP16.03CP16.03Veltkamp Floor Mak-Nienhuis Elske M. Haverman Lotte Bouts Antonia H. M. http://dx.doi.org/10.13039/501100009248Innovatiefonds ZorgverzekeraarsDr. C.J. Vaillantfonds

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T17:03:02.914902+00:00

DOI: 10.1007/s00431-023-05135-5 · PMC10587200